Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study.
OBJECTIVE: There is considerable interindividual variation in sulfonylurea response in type 2 diabetes. Transcription factor 7-like 2 (TCF7L2) variants have been identified to be strongly associated with type 2 diabetes risk, probably due to decreased beta-cell function. We hypothesized that variat...
Autores principales: | Pearson, E, Donnelly, L, Kimber, C, Whitley, A, Doney, A, McCarthy, M, Hattersley, A, Morris, A, Palmer, C |
---|---|
Formato: | Journal article |
Lenguaje: | English |
Publicado: |
2007
|
Ejemplares similares
-
Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study.
por: Zhou, K, et al.
Publicado: (2009) -
TCF7L2 in the Go-DARTS study: evidence for a gene dose effect on both diabetes susceptibility and control of glucose levels.
por: Kimber, C, et al.
Publicado: (2007) -
Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.
por: Zhou, K, et al.
Publicado: (2010) -
Pharmacogenetics in Type 2 diabetes: variation in TCF7L2 influences response to sulphonylureas
por: Pearson, E, et al.
Publicado: (2007) -
Metformin Pharmacogenetics and SLC2A2: Genome-Wide Association Study and 2-stage replication in GoDARTS and UKPDS
por: Zhou, K, et al.
Publicado: (2013)